Dermaliq
Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men. What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…
Read MoreA subsidiary of a European pharmaceutical company has launched in the US to trial a new drug against pattern hair loss. Also, preclinical data from the stock market-traded company Omega Therapeutics is shown. Dermaliq DLQ01 Drug Candidate On January 18, 2022, Novaliq GmbH and strategic investment partners announced the formation of a Dermaliq Therapeutics Inc.,…
Read More